Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06912646 · ClinicalTrials.gov registry record · NA
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
A NA study of Neuropathy and Neuropathy;Peripheral, sponsored by Erchonia Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06912646: Recruiting NA study of Neuropathy and Neuropathy;Peripheral, sponsored by Erchonia Corporation.
NCT06912646 is a NA study of Neuropathy and Neuropathy;Peripheral that is actively recruiting participants, run by Erchonia Corporation. The registered enrollment target is 32 participants, below the 185-participant average among 22 other Neuropathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06912646, a NA study of Neuropathy and Neuropathy;Peripheral, is actively recruiting participants, sponsored by Erchonia Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.
Primary Outcome
The Visual Analog Scale (VAS) will be used to assess pain from baseline to the 6-week endpoint for each subject. Subjects will be instructed to indicate the overall level of pain experienced in their feet by placing a cross (X) on a 10-centimeter horizontal line. The left end of the line will be labeled "0," representing "no pain," and the right end will be labeled "100," representing "the worst pain imaginable." Individual subject success is defined as a 30% or greater change in VAS pain scores
Conditions Studied
Interventions
- DEVICE Erchonia® EVRL™
Study Locations (1)
Florida
- Franco & Co - Miramar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-06-16 |
| Phase | NA |
What NCT06912646 shows while recruiting
NCT06912646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 185-participant average among 22 other Neuropathy trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Erchonia® EVRL™ is the first listed.
NCT06912646 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06912646 about?
NCT06912646 is a clinical study titled "Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain". The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy ...
What is the current status of trial NCT06912646?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-05-01. Estimated completion is 2027-06-16.
What conditions does trial NCT06912646 study?
This clinical trial studies the following conditions: Neuropathy, Neuropathy;Peripheral.
What interventions are being tested in trial NCT06912646?
The interventions under investigation include: Erchonia® EVRL™ (DEVICE).
Who is sponsoring clinical trial NCT06912646?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06912646 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06912646's enrollment target sits among peer trials
32 19th of 22 higher than 4 of 22 other Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
RECRUITING · NA
-
Daily Hand-Held Vibration Therapy
RECRUITING · NA
-
Improving Autonomic Function and Balance in Diabetic Neuropathy
ACTIVE NOT RECRUITING · NA
-
rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy
ACTIVE NOT RECRUITING · NA
-
The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
ACTIVE NOT RECRUITING · NA
-
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI